Home > Healthcare > Medical Devices > Therapeutic Devices > Brachytherapy Devices Market
Brachytherapy Devices Market size was valued at USD 716 Million in 2022 and is estimated to account for USD 1.3 billion by 2032.
Brachytherapy devices are specialized medical devices used in several cancer disease treatments. Brachytherapy involves placing radioactive sources directly near or within tumors for precise treatment. These devices offer accurate positioning and delivery of radiation while minimizing harm to healthy tissues. Brachytherapy devices enable focused cancer treatment, enhancing effectiveness and reducing side effects. The increasing prevalence of cancer and heightened awareness are some of the major factors driving the demand for advanced treatments such as precise brachytherapy.
The escalating incidence rate of cancer globally is a significant driver for the brachytherapy devices market. For instance, according to the 2023 report from the Pan American Health Organization (PAHO), there were approximately 20 million new cancer cases and 10 million cancer-related deaths globally. Moreover, projections suggest that the burden of cancer could increase by about 60% over the next two decades and it is anticipated that the number of new global cancer cases will reach around 30 million by the year 2040.
Therefore, as cancer becomes more prevalent, the high demand for effective treatment methods such as brachytherapy will boost revenue growth. Furthermore, public awareness campaigns, education initiatives, and advocacy efforts are contributing to a deeper understanding of cancer, its risks, and available treatment options. Patients are becoming more informed and proactive in making healthcare decisions. Therefore, this heightened awareness also extends to brachytherapy, as patients and healthcare professionals are recognizing its benefits in providing localized treatment while minimizing harm to healthy tissues.
Report Attribute | Details |
---|---|
Base Year: | 2022 |
Brachytherapy Devices Market Size in 2022: | USD 716 Million |
Forecast Period: | 2023 to 2032 |
Forecast Period 2023 to 2032 CAGR: | 6.2% |
2032 Value Projection: | USD 1.3 Billion |
Historical Data for: | 2018 to 2022 |
No. of Pages: | 337 |
Tables, Charts & Figures: | 420 |
Segments covered: | Product Type, Technique, Application, End-use, and Region |
Growth Drivers: |
|
Pitfalls & Challenges: |
|
The emergence of the COVID-19 pandemic significantly impaired the brachytherapy devices market. The COVID-19 outbreak instigated disruptions across global healthcare systems and affected diverse aspects of medical treatment, including brachytherapy. This crisis prompted a redirection of healthcare resources towards managing the pandemic and caused delays and interruptions in planned medical imaging and treatment procedures, including cancer diagnostics and treatments such as brachytherapy.
Moreover, access to healthcare facilities was constrained by lockdowns, travel restrictions, and safety concerns that led to treatment postponements. Furthermore, hospitals had to adapt to new safety protocols, diverted resources to COVID-19 care, and reduced capacity for procedures including brachytherapy. Additionally, economic uncertainties induced some patients to delay seeking necessary medical care.
Rapid technological progress has significantly enhanced the precision and effectiveness of brachytherapy. For instance, Isoray Medical, Inc. obtained clearance from the U.S. Food and Drug Administration (FDA) to utilize C4 Imaging's Sirius markers, which produce positive MRI (Magnetic Resonance Imaging) signals, in conjunction with Isoray's Cesium-131 brachytherapy seeds. Thus, advanced imaging techniques such as Magnetic Resonance Imaging (MRI), Computerized Tomography (CT) scans, and Positron Emission Tomography (PET) scans enable medical professionals to accurately visualize tumor sites, aiding in treatment planning. Furthermore, computerized treatment planning systems allow intricate customization of radiation doses and angles to optimize therapy outcomes. Therefore, such advancements enhance the procedural success rate as well as reduce potential side effects for patients thereby, stimulating the market progress.
Additionally, growing government initiatives, Funding for cancer research & development, developing healthcare infrastructure, and patient support programs will spur the adoption of advanced cancer treatment methods, including brachytherapy, and propelling market revenue.
The brachytherapy devices market by product type is categorized into seeds, applicators & afterloaders, and electronic brachytherapy. The seeds segment garnered USD 464 million revenue size in the year 2022. The dominance of the segment can be attributed to its remarkable precision in radiation delivery, significantly reducing damage to healthy tissues. Furthermore, the minimally invasive nature of seed implantation contributes to quicker patient recovery and more efficient healthcare resource utilization. Continuous advancements in materials, designs, and delivery mechanisms will further improve the safety and effectiveness of seeds-based brachytherapy.
Additionally, Seeds offer versatility in treating various cancers, such as prostate, breast, and gynecological cancers among others will enhance patient preference thereby propelling segment demand.
Based on technique, the brachytherapy devices market is segmented into high dose rate (HDR) and low dose rate (LDR). The low dose rate (LDR) segment accounted for 78.5% market share in the year 2022 and is anticipated to witness the highest growth during the forecast period. High segment growth is attributable to its controlled radiation release and compatibility with personalized medicine. The LDR technique's gradual radiation delivery effectively targets tumors while minimizing damage to healthy tissue and this approach also aligns with the trend of tailored treatments, enhancing outcomes and reducing side effects.
Based on application, the brachytherapy devices market is segmented into gynecological cancer, prostate cancer, breast cancer, and others. The prostate cancer segment accounted for over 68.2% business share in the year 2022 and is anticipated to witness lucrative growth during the forecast period. The widespread occurrence of prostate cancer has driven increased demand for effective treatment options. In addition, positioning brachytherapy gaining popularity due to its ability to deliver precise radiation directly to the prostate while minimizing damage to surrounding tissues.
For instance, the American Cancer Society's projections for prostate cancer in the U.S. in 2023 indicate an estimated 288,300 new cases of prostate cancer and around 34,700 deaths attributed to this condition. Consequently, the continued prominence of brachytherapy for prostate cancer is poised to stimulate segmental market growth, fuelled by the rising prostate cancer prevalence and ongoing advancements in treatment technology that promise even greater precision and efficacy.
The brachytherapy devices market by end-use is categorized into hospitals, specialty clinics, and others. The hospital segment garnered USD 411.2 million revenue size in 2022. Hospitals possess advanced imaging and treatment planning systems, ensuring seamless integration of brachytherapy into patient care. High investment in advanced technologies and specialized cancer care will drive the demand for brachytherapy. Further, a strong presence of specialized healthcare professionals and comprehensive treatment solutions will continue to support the expansion of the brachytherapy device market in the hospitals segment.
The U.S. brachytherapy devices market accounted for USD 270.5 million revenue size in 2022 and is predicted to witness substantial market growth over the analysis timeline. Increasing geriatric population base along with the rising incidence of cancer in the country will drive the U.S. market progress. For instance, as per the 2023 report from the Pan American Health Organization (PAHO), the Americas region is anticipating a 57% increase in the number of cancer diagnoses and the projections also indicate that approximately 6.23 million individuals will be expected to receive cancer diagnoses by the year 2040. Thus, the rising prevalence rate of cancer will contribute to the market growth.
Some of the eminent market participants operating in the brachytherapy devices market include
These market players are undertaking several growth strategies including partnerships, collaborations, acquisitions & mergers, and new product development & launches to strengthen their product portfolio as well as gain a competitive edge over others.
Click here to Buy Section of this Report
By Product Type (USD Million and Units)
By Technique (USD Million)
By Application (USD Million)
By End-use (USD Million)
The above information is provided for the following regions and countries: